查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968071

全球抗體藥物複合體契約製造市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Antibody Drug Conjugates Contract Manufacturing Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 113 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

抗體藥物複合體(ADC)契約製造市場預計將從 2025 年的 103.7 億美元成長到 2034 年的 274.5 億美元，2026 年至 2034 年的複合年成長率為 11.42%。

隨著抗體藥物複合體（ADC）作為一種創新癌症治療方法的出現，全球抗體藥物複合體合約契約製造市場正在迅速擴張。製藥公司擴大將複雜的生產流程外包，包括單株抗體、細胞毒性有效載荷和連接子技術。 ADC生產相關的技術複雜性和高額資金需求，正在強化全球專業契約製造公司的角色。

推動成長的主要因素包括不斷擴充的腫瘤治療產品線、癌症發生率的上升以及抗體偶聯藥物（ADC）療法監管核准的增加。偶聯技術和標靶藥物遞送機制的進步正在提升治療效果和安全性。此外，生物製藥公司正在尋求靈活的生產模式，以有效地完成從臨床到商業規模的過渡，從而催生了對整合式合約研發生產（CDMO）服務的強勁需求。

隨著新一代抗體偶聯藥物（ADC）的適應症擴大至腫瘤以外的更廣泛領域，其未來前景仍十分光明。持續投資於高等級生物安全設施和先進的生物製程能力將助力市場擴張。策略聯盟和併購將強化服務組合，確保ADC契約製造產業持續成為精準醫療創新不可或缺的基石。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球抗體藥物複合體契約製造市場：依條件分類

  • 市場分析、洞察與預測
  • 多發性骨髓瘤
  • 淋巴瘤
  • 乳癌
  • 其他

第5章：全球抗體藥物複合體契約製造市場：依連接子分類

  • 市場分析、洞察與預測
  • 可切割連接器
  • 不可切割的連接子

第6章 全球抗體藥物複合體契約製造市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Sterling
    • Recipharm AB
    • Lonza
    • Catalent Inc
    • Sartorius AG
    • Wuxi Biologics
    • Samsung Biologics
    • Piramal Group（Piramal Pharma Solutions）
    • AbbVie Inc.（AbbVie Contract Manufacturing）
    • Merck KGaA
簡介目錄
Product Code: VMR112110154

The Antibody Drug Conjugates Contract Manufacturing Market size is expected to reach USD 27.45 Billion in 2034 from USD 10.37 Billion (2025) growing at a CAGR of 11.42% during 2026-2034.

The Global Antibody Drug Conjugates Contract Manufacturing Market is expanding rapidly as ADCs emerge as a transformative oncology treatment modality. Pharmaceutical companies are increasingly outsourcing complex manufacturing processes involving monoclonal antibodies, cytotoxic payloads, and linker technologies. The technical intricacies and high capital requirements associated with ADC production have strengthened the role of specialized contract manufacturers worldwide.

Growth is primarily driven by the expanding oncology pipeline, rising cancer prevalence, and increasing regulatory approvals for ADC therapies. Advances in conjugation technologies and targeted drug delivery mechanisms have improved therapeutic efficacy and safety profiles. Additionally, biopharma firms are seeking flexible production models to manage clinical-to-commercial scale transitions efficiently, creating strong demand for integrated CDMO services.

Future prospects remain highly promising as next-generation ADCs target broader indications beyond oncology. Continuous investments in high-containment facilities and advanced bioprocessing capabilities will support market expansion. Strategic collaborations and mergers are expected to enhance service portfolios, ensuring the ADC contract manufacturing sector remains a critical backbone of precision medicine innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Condition

  • Myeloma
  • Lymphoma
  • Breast Cancer
  • Others

By Linker

  • Cleavable Linker
  • Non-cleavable Linker

COMPANIES PROFILED

  • Sterling, Recipharm AB, Lonza, Catalent Inc, Sartorius AG, Wuxi Biologics, Samsung Biologics, Piramal Group Piramal Pharma Solutions, AbbVie Inc AbbVie Contract Manufacturing, Merck KGaA
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: BY CONDITION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Condition
  • 4.2. Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: BY LINKER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Linker
  • 5.2. Cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Non-cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Condition
    • 6.2.2 By Linker
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Condition
    • 6.3.2 By Linker
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Condition
    • 6.4.2 By Linker
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Condition
    • 6.5.2 By Linker
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Condition
    • 6.6.2 By Linker
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Sterling
    • 8.2.2 Recipharm AB
    • 8.2.3 Lonza
    • 8.2.4 Catalent Inc
    • 8.2.5 Sartorius AG
    • 8.2.6 Wuxi Biologics
    • 8.2.7 Samsung Biologics
    • 8.2.8 Piramal Group (Piramal Pharma Solutions)
    • 8.2.9 AbbVie Inc. (AbbVie Contract Manufacturing)
    • 8.2.10 Merck KGaA